ZA201407685B - Substituted pyridine compounds as crac modulators - Google Patents

Substituted pyridine compounds as crac modulators

Info

Publication number
ZA201407685B
ZA201407685B ZA2014/07685A ZA201407685A ZA201407685B ZA 201407685 B ZA201407685 B ZA 201407685B ZA 2014/07685 A ZA2014/07685 A ZA 2014/07685A ZA 201407685 A ZA201407685 A ZA 201407685A ZA 201407685 B ZA201407685 B ZA 201407685B
Authority
ZA
South Africa
Prior art keywords
substituted pyridine
pyridine compounds
crac modulators
crac
modulators
Prior art date
Application number
ZA2014/07685A
Other languages
English (en)
Inventor
Venkata P Palle
Neelima Sinha
Gokul Keruji Deshmukh
Vijay Pandurang Karche
Zubair Abdul Wajid Shaikh
Nageswara Rao Irlapati
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of ZA201407685B publication Critical patent/ZA201407685B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2014/07685A 2012-05-02 2014-10-22 Substituted pyridine compounds as crac modulators ZA201407685B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6KO2012 2012-05-02
PCT/IB2013/053440 WO2013164769A1 (en) 2012-05-02 2013-05-01 Substituted pyridine compounds as crac modulators

Publications (1)

Publication Number Publication Date
ZA201407685B true ZA201407685B (en) 2015-11-25

Family

ID=48428565

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/07685A ZA201407685B (en) 2012-05-02 2014-10-22 Substituted pyridine compounds as crac modulators

Country Status (7)

Country Link
US (2) US9399638B2 (enExample)
EP (1) EP2844655A1 (enExample)
AU (1) AU2013255437A1 (enExample)
CA (1) CA2871270A1 (enExample)
IN (1) IN2014MN02126A (enExample)
WO (1) WO2013164769A1 (enExample)
ZA (1) ZA201407685B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
US9790231B2 (en) 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
WO2015090579A1 (en) * 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
CN105367547B (zh) * 2014-08-19 2019-04-23 北京桦冠生物技术有限公司 一种噁唑啉酮抗生素的新合成工艺
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP2018500388A (ja) 2014-11-18 2018-01-11 ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー
EP3778595B1 (en) * 2015-02-27 2021-08-25 Calcimedica, Inc. Pancreatitis treatment
WO2016187182A1 (en) 2015-05-18 2016-11-24 Beth Israel Deaconess Medical Center, Inc. Substance p, mast cell degranulation inhibitors, and peripheral neuropathy
PL3303330T3 (pl) * 2015-06-03 2019-10-31 Bristol Myers Squibb Co Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych
EP3331525B1 (en) 2015-08-07 2020-10-07 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
WO2017201313A1 (en) 2016-05-18 2017-11-23 Shengkan Jin Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US11919902B2 (en) 2017-12-22 2024-03-05 Hibercell, Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
MX2021003094A (es) 2018-09-14 2021-05-12 Rhizen Pharmaceuticals A G Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas.
US12187703B2 (en) 2019-05-13 2025-01-07 Novartis Ag Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法
US12522589B2 (en) 2020-11-13 2026-01-13 Calcimedica, Inc. Synthesis of CRAC channel inhibitors
EP4516778A1 (en) 2022-04-25 2025-03-05 Nippon Shinyaku Co., Ltd. Compound serving as ddr1 kinase inhibitor, and medicine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533594C (en) 2003-07-23 2013-04-02 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
JP2008513508A (ja) 2004-09-21 2008-05-01 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫に関連する用途に用いる化合物
MX2007008290A (es) 2005-01-07 2008-02-15 Synta Pharmaceuticals Corp Compuestos para inflamacion y usos inmuno-relacionados.
EP1848435B1 (en) 2005-01-25 2016-01-20 Synta Pharmaceuticals Corp. Compounds against inflammations and immune-related uses
WO2006081389A1 (en) 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
WO2007087429A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
TW200806290A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted biaryl compounds for inflammation and immune-related uses
EP1983971A4 (en) 2006-01-25 2010-11-24 Synta Pharmaceuticals Corp SUBSTITUTED AROMATIC COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS
AU2007211276B2 (en) 2006-01-31 2013-06-06 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
JP5349306B2 (ja) 2006-08-21 2013-11-20 ジェネンテック, インコーポレイテッド アザベンゾチオフェニル化合物および使用方法
US20120064121A1 (en) 2007-08-01 2012-03-15 Synta Pharmaceuticals Corp. Pyridine compounds for inflammation and immune-related uses
US8598208B2 (en) 2007-08-17 2013-12-03 Actelion Pharmaceuticals Ltd. Pyridine derivatives as S1P1/EDG1 receptor modulators
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2009076454A2 (en) 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP5474941B2 (ja) 2008-05-23 2014-04-16 グラクソ グループ リミテッド 窒素含有三環式化合物およびその抗菌剤としての使用
DE102008031299B4 (de) 2008-07-02 2014-10-30 Acandis Gmbh & Co. Kg Filter für ein Blutgefäß
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
CA2739303A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AR077971A1 (es) 2009-08-26 2011-10-05 Astrazeneca Ab Derivados heterociclicos de urea y metodos de uso de los mismos
WO2011034962A2 (en) 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
AP3341A (en) 2010-10-30 2015-07-31 Lupin Ltd Oxazoline and isoxazoline derivatives as crac modulators
ES2660996T3 (es) 2011-05-03 2018-03-27 PRCL Research Inc. Compuestos para la inflamación y usos relacionados con el sistema inmunitario
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2853469A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium

Also Published As

Publication number Publication date
CA2871270A1 (en) 2013-11-07
US20150111900A1 (en) 2015-04-23
AU2013255437A1 (en) 2014-11-13
EP2844655A1 (en) 2015-03-11
IN2014MN02126A (enExample) 2015-09-11
US20160304506A1 (en) 2016-10-20
US9399638B2 (en) 2016-07-26
WO2013164769A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
ZA201407685B (en) Substituted pyridine compounds as crac modulators
SG11201406274VA (en) Novel compounds
GB201207406D0 (en) Novel compounds
IL239447A0 (en) new compounds
IL238800A0 (en) new compounds
GB201212871D0 (en) Novel compounds
ZA201508864B (en) Substituted heterocyclic compounds as crac modulators
ZA201407668B (en) Substituted pyrazole compounds as crac modulators
GB201209986D0 (en) Novel compounds
IL280595A (en) new compounds
GB201222711D0 (en) Novel compounds
GB201207392D0 (en) Novel compounds
GB201209670D0 (en) Novel compounds
SG11201504418TA (en) Pyridone compound
GB201212816D0 (en) Novel compounds
GB201220560D0 (en) Novel compounds ll
GB201222419D0 (en) Novel compounds
GB201222430D0 (en) Novel compounds
GB201222435D0 (en) Novel compounds
GB201222433D0 (en) Novel compounds
GB201222393D0 (en) Novel compounds
GB201219554D0 (en) Novel compounds
GB201219472D0 (en) Novel compounds
GB201217387D0 (en) Novel compounds
GB201216548D0 (en) Novel compounds